Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Lam ET, Au JL, Otterson GA, Guillaume Wientjes M, Chen L, Shen T, Wei Y, Li X, Bekaii-Saab T, Murgo AJ, Jensen RR, Grever M, Villalona-Calero MA. Lam ET, et al. Among authors: murgo aj. Cancer Chemother Pharmacol. 2010 Nov;66(6):1019-29. doi: 10.1007/s00280-010-1252-x. Epub 2010 Jan 28. Cancer Chemother Pharmacol. 2010. PMID: 20107799 Free PMC article. Clinical Trial.
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, Murgo AJ, Jensen R, Yeh TK, Wei Y, Zhang Y, Eng C, Grever M, Au JL. Villalona-Calero MA, et al. Among authors: murgo aj. Ann Oncol. 2008 Nov;19(11):1903-9. doi: 10.1093/annonc/mdn412. Epub 2008 Jul 15. Ann Oncol. 2008. PMID: 18632723 Free PMC article. Clinical Trial.
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors.
Pavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, Wadler S, Farrell K, Carr M, Fry D, Murgo AJ, Oratz R, Hochster H, Liebes L, Muggia F. Pavlick AC, et al. Among authors: murgo aj. Cancer Chemother Pharmacol. 2009 Sep;64(4):803-10. doi: 10.1007/s00280-009-0931-y. Epub 2009 Feb 17. Cancer Chemother Pharmacol. 2009. PMID: 19221754 Free PMC article. Clinical Trial.
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Figg WD, Monga M, Headlee D, Shah A, Chau CH, Peer C, Messman R, Elsayed YA, Murgo AJ, Melillo G, Ryan QC, Kalnitskiy M, Senderowicz AM, Hollingshead M, Arbuck SG, Sausville EA. Figg WD, et al. Among authors: murgo aj. Cancer Chemother Pharmacol. 2014 Nov;74(5):955-67. doi: 10.1007/s00280-014-2569-7. Epub 2014 Sep 3. Cancer Chemother Pharmacol. 2014. PMID: 25183650 Free PMC article. Clinical Trial.
Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.
Kummar S, Gutierrez ME, Anderson LW, Klecker RW Jr, Chen A, Murgo AJ, Doroshow JH, Collins JM. Kummar S, et al. Among authors: murgo aj. Cancer Chemother Pharmacol. 2013 Oct;72(4):917-23. doi: 10.1007/s00280-013-2244-4. Epub 2013 Aug 3. Cancer Chemother Pharmacol. 2013. PMID: 23912694 Free PMC article. Clinical Trial.
119 results